Researchers at Pitt have developed fully human anti-cluster of differentiation-22 (CD22) engineered antibody VH domains as potential therapeutic targets for treating B cell malignancies and other lymphoid cancers.
Description
This invention is a decision-support tool designed to aid critical care practitioners in setting the rate of net fluid removal during continuous kidney replacement therapy. The algorithm uses patient-specific data, including predicted body weight and fluid infusion rate, to optimize the fluid removal process. Currently, there is no standardized method for determining this rate, leading to significant variations in clinical practice. By providing a systematic approach, this tool could reduce complications like hypotension, cardiac arrhythmias, and fluid overload, ultimately improving patient survival.
Applications
- Kidney replacement therapy (dialysis) in critical care settings
- Acute kidney injury management
- Standardizing fluid removal protocols
- Decision-support tool for ICU nurses and physician
Advantages
This fluid removal algorithm represents a significant advancement in the management of acute kidney injury. It offers a standardized approach where none previously existed, potentially reducing the wide variation in clinical practices. By optimizing fluid removal rates, the tool aims to mitigate the risks of both overly aggressive and insufficient fluid removal. The algorithm can be integrated into existing dialysis machines or developed into an app, making it versatile for various clinical applications. It addresses a critical need in ICU settings where precise fluid management is vital for patient outcomes.
Invention Readiness
The algorithm has been incorporated into an Excel-based tool, currently being validated through an NIH-funded clinical trial. Once the trial is complete, the tool is expected to be published and made available for integration into clinical practice. Collaboration with Mayo Clinic and potential interest from dialysis machine manufacturers indicate strong commercial potential.
IP Status
Patent Pending
